Stoke Therapeutics Overview
Stoke Therapeutics Target Price
Analysts' 12-month price predictions for STOK.
Get informed when a big investor buys or sells
+ FollowShare Price
$32.7
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-02-23 | Wolfe Research | $40 |  22.3% upside |  |
| 2026-02-05 | GuggenheimYatin Suneja | $60 | 83.5% upside | |
| 2026-01-12 | Wedbush | $36 | 10.1% upside | |
| 2026-01-05 | Canaccord Genuity | $36 | 10.1% upside | |
| 2026-01-05 | Loop Capital MarketsKeay Nakae | $35 | 7% upside | |
| 2025-12-16 | H.C. WainwrightAndrew Fein | $50 | 52.9% upside | |
| 2025-12-15 | UBS | $50 | 52.9% upside | |
| 2025-11-05 | Canaccord Genuity | $28 |  14.4% downside | |
| 2025-10-10 | Needham | $35 | 7% upside | |
| 2025-08-18 | BTIGThomas Shrader | $28 | 14.4% downside | |
| 2024-10-11 | Leerink PartnersMarc Goodman | $18 | 45% downside | |
| 2024-09-11 | H.C. WainwrightDebjit Chattopadhyay | $35 | 7% upside | |
| 2024-05-07 | Canaccord GenuitySumant Kulkami | $20 | 38.8% downside | |
| 2024-03-26 | NeedhamJoseph Stringer | $22 | 32.7% downside | |
| 2024-03-26 | Canaccord GenuitySumant Kulkami | $21 | 35.8% downside | |
| 2022-11-14 | Needham | $25 | 23.5% downside | |
| 2021-04-26 | Credit SuisseJudah Frommer | $58 | 77.4% upside | |